HUTCHMED (China) Ltd (HCM) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
HUTCHMED (China)’s revenue went from $216M in fiscal 2016 to $549M in fiscal 2025, growth of about 10.9% a year.
Net income in fiscal 2025 was $457M, a net margin of 83.3%; the highest of the period.
Over the twelve months to June 30, 2026, revenue was $549M and net income $18M.
Free cash flow was -$79M in fiscal 2025 and positive in 1 of the 10 years shown.
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $549M | $549M | $630M | $838M | $426M | $356M | $228M | $205M | $214M | $241M | $216M |
| Gross profit | — | $212M | $281M | $454M | $115M | — | — | — | — | $71M | $67M |
| Operating income | — | -$39M | -$44M | $18M | -$408M | -$328M | -$197M | -$146M | -$93M | -$53M | -$47M |
| Net income | $18M | $457M | $38M | $101M | -$361M | -$195M | -$126M | -$106M | -$75M | -$27M | $12M |
| EPS (diluted) | $0.10 | $2.62 | $0.22 | $0.58 | $-2.07 | $-1.12 | $-0.72 | $-0.61 | $-0.43 | $-0.15 | $0.07 |
| R&D | — | $148M | $212M | $302M | $387M | $299M | $175M | $138M | $114M | $76M | $67M |
| Revenue growth | — | −13.0% | −24.8% | +96.5% | +19.7% | +56.2% | +11.3% | −4.3% | −11.2% | +11.6% | +21.2% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $20M | -$65M | $497000 | $219M | -$269M | -$204M | -$62M | -$81M | -$33M | -$9M | -$10M |
| Capital spending | -$11M | -$14M | -$18M | -$33M | -$37M | -$16M | -$8M | -$9M | -$6M | -$5M | -$4M |
| Free cash flow | $10M | -$79M | -$17M | $187M | -$305M | -$221M | -$70M | -$89M | -$39M | -$14M | -$14M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | $36M | $9M | $48M | $27M | $13M | $346000 | $5M | $1M | $604000 |
| Stock-based pay | — | — | — | — | — | — | — | — | — | — | — |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $1.4B | $836M | $886M | $631M | $1.0B | $435M | $217M | $301M | $358M | $104M |
| Debt | — | $98M | $90M | $86M | $27M | $39M | $36M | $33M | $33M | $30M | $47M |
| Equity | — | $1.2B | $760M | $731M | $610M | $987M | $484M | $288M | $389M | $462M | $184M |
| Total assets | — | $1.8B | $1.3B | $1.3B | $1.0B | $1.4B | $724M | $465M | $532M | $598M | $342M |
| Shares (diluted) | 175M | 174M | 174M | 174M | 174M | 174M | 174M | 174M | 174M | 174M | 174M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | 38.7% | 44.6% | 54.1% | 27.0% | — | — | — | — | 29.6% | 31.0% |
| Operating margin | — | -7.1% | -6.9% | 2.2% | -95.6% | -92.2% | -86.3% | -71.5% | -43.3% | -22.1% | -21.6% |
| Net margin | 3.3% | 83.3% | 6.0% | 12.0% | -84.6% | -54.7% | -55.1% | -51.7% | -34.9% | -11.1% | 5.4% |
| FCF margin | 1.8% | -14.4% | -2.8% | 22.3% | -71.6% | -62.0% | -30.7% | -43.7% | -18.3% | -5.8% | -6.4% |
| ROIC | — | -2.6% | -4.1% | 2.1% | -63.9% | -25.3% | -29.9% | -36.0% | -17.3% | -8.6% | -15.9% |
| ROE | — | 36.9% | 5.0% | 13.8% | -59.1% | -19.7% | -26.0% | -36.8% | -19.2% | -5.8% | 6.3% |
Frequently asked questions
What is HUTCHMED (China)’s annual revenue?
$549M in fiscal 2025 and $549M over the twelve months to June 30, 2026.
How much profit does HUTCHMED (China) make?
Net income was $457M in fiscal 2025 (net margin 83.3%).
Is HUTCHMED (China)’s revenue growing?
No: revenue fell 13.0% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.